New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
The cGMP-4 facility will further strengthen the company's ability to serve global partners
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
The facility has been designed with a dual focus on efficiency and sustainability
The payment is in accordance with the agreed contractual terms
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
He has been associated with the Zydus Group since 2009
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
